ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing

Rhea-AI Summary

ALZpath announced a global licensing agreement with Abbott (NYSE: ABT) to use ALZpath’s proprietary pTau217 antibody in developing an in vitro diagnostic blood test for Alzheimer’s disease on Abbott’s Alinity ci-series systems.

The antibody is supported by 200+ publications across 18 countries and aims to offer a scalable blood-based alternative to PET imaging and cerebrospinal fluid analysis for earlier Alzheimer’s detection and potential disease monitoring.

News Market Reaction – ABT

-0.04%

1 alert

-0.04% Session close to close

$164.51B Market Cap

0.3x Rel. Volume

In the Jun 24 session, ABT declined 0.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores ABT’s diagnostics scale, adding a pTau217-based Alzheimer’s test oppor...

Analysis

This announcement underscores ABT’s diagnostics scale, adding a pTau217-based Alzheimer’s test opportunity via Alinity systems. Extensive validation supports the biology, while an active S-3 shelf and low short interest frame capital-raising and volatility risks to monitor.

Key Figures

Peer-reviewed publications: more than 200 publications Countries with data: 18 countries Director share purchase: 2,000 shares at $86.82 +5 more

8 metrics

Peer-reviewed publications more than 200 publications Validation of ALZpath pTau217 antibody across multiple studies

Countries with data 18 countries Geographic breadth of clinical validation for pTau217 antibody

Director share purchase 2,000 shares at $86.82 Open-market buy by director John G. Stratton on May 7, 2026

Proposed Rule 144 sale 7,587 shares Planned sale of common stock under Rule 144

Shares sold 29,211 shares Sale of common stock reported in Rule 144 filing by Robert J. Alpern

Vanguard ownership 130,676,776 shares (7.5%) Beneficial stake reported in Schedule 13G

Shares outstanding 1,737,682,887 shares Common shares outstanding as of January 31, 2026 in S-3ASR

Authorized shares 2,400,000,000 shares Authorized common shares referenced in shelf prospectus

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	Consumer survey update	Positive	-0.2%	Similac survey and authenticity‑focused parenting initiative announcement.
Jun 12	Dividend declaration	Positive	-2.1%	410th consecutive quarterly dividend declaration with long dividend‑growth record.
Jun 08	Clinical program data	Positive	+0.1%	New Healthy Food Rx data showing improved outcomes in type 2 diabetes.
May 27	CE Mark clearance	Positive	-1.1%	CE Mark for dual glucose‑ketone Libre Duo sensing systems in Europe.
May 27	Guideline reaffirmation	Positive	-1.1%	ACS guidelines reaffirm noninvasive colorectal cancer tests as preferred options.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ABT has often shown flat to negative next‑day moves following generally positive corporate news.

Key Terms

phosphorylated tau 217 (ptau217), in vitro diagnostic (ivd), cerebrospinal fluid (csf), biomarkers

4 terms

phosphorylated tau 217 (ptau217) medical

"to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development"

Phosphorylated tau 217 (ptau217) is a specific form of the brain protein tau that carries a phosphate tag at the 217th amino acid and can be measured in blood or spinal fluid as a marker of nerve‑cell damage associated with Alzheimer’s pathology. Like a smoke alarm for early disease changes, ptau217 helps clinicians and researchers detect disease, select appropriate patients and track treatment effects, so advances in tests or drugs tied to this marker can drive commercial, clinical and regulatory value.

in vitro diagnostic (ivd) medical

"into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease"

In vitro diagnostic (IVD) tests are medical tests run on samples such as blood, urine or swabs outside the body to detect diseases, measure biomarkers or guide treatment decisions. Investors pay attention because IVDs generate recurring sales for test kits and instruments, are heavily influenced by regulatory approval, reimbursement and accuracy, and can quickly shift market value when a test becomes widely adopted or replaced — like a trusted household tool that professionals rely on every day.

cerebrospinal fluid (csf) medical

"alternative to PET imaging and cerebrospinal fluid (CSF) analysis, which are costly"

Cerebrospinal fluid (CSF) is a clear liquid that surrounds and cushions the brain and spinal cord, providing protection and helping to remove waste. Although it is a medical term, in a financial context, understanding how resources and support flow within a system can be similar to how CSF circulates and maintains the health of the nervous system. Recognizing such fundamental processes can offer insights into the stability and resilience of broader systems, including financial markets.

biomarkers medical

"Blood-based biomarkers may also play a role in monitoring disease progression"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale

CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE: ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease. The test would be designed for use on Abbott's Alinity ci-series systems, which represents one of the largest install bases of immunoassay instruments worldwide.

ALZpath's pTau217 antibody is among the most clinically validated for detecting Alzheimer's disease pathology. Backed by more than 200 peer-reviewed publications across 18 countries, the antibody demonstrates high accuracy and sensitivity in identifying Alzheimer's disease biology.

"This agreement further strengthens ALZpath's leadership in blood-based Alzheimer's testing and reinforces our position as the foundational component supporting the overwhelming majority of the pTau217 IVD market," said Mike Banville, CEO of ALZpath. "As blood-based biomarkers become central to how Alzheimer's disease is detected and managed, partnering with a global healthcare leader like Abbott can enable high-performance testing to reach clinicians and patients around the world at scale. Together with our diagnostic partners, we remain focused on bringing our highly accurate and sensitive antibody into routine care, including primary care, to reach patients in need."

As disease-modifying therapies continue to expand, accessible diagnostics are essential for earlier patient identification. ALZpath's pTau217 antibody offers a scalable alternative to PET imaging and cerebrospinal fluid (CSF) analysis, which are costly, invasive, and difficult to deploy at scale. Blood-based biomarkers may also play a role in monitoring disease progression and treatment response in routine clinical practice.

"Abbott has spent more than a decade advancing brain health science to give clinicians earlier, clearer answers," said John Frels, vice president of research and development in Abbott's Core Diagnostics business. "Our work – including pioneering the first FDA cleared rapid blood test that helps assess mild traumatic brain injuries by providing objective biomarker data – shows what's possible when we deepen our understanding of the brain. Collaborations like this are accelerating the next era of Alzheimer's disease research, clinical trials for therapies and ultimately patient care."

About ALZpath

ALZpath, Inc. is a leader in blood test-based diagnostic solutions for Alzheimer's disease. Its proprietary pTau217 antibody, used in many of the most advanced and widely available blood-based tests, is helping transform how Alzheimer's disease is detected, treated, and monitored. Through licensing agreements with global industry leaders along with collaborations with world-class laboratories, ALZpath is expanding access to earlier, more scalable detection. ALZpath's innovations have earned multiple honors, including Time Magazine Best Inventions (2024), Fast Company Most Innovative Companies (2025), and BioTech Breakthrough "Diagnostic Innovation of the Year" (2025). To learn more, visit https://alzpath.bio/ and follow ALZpath on LinkedIn, X, BlueSky, and Facebook.

ALZpath Media Contact:
Jessica Hoffman
FINN Partners
Jessica.hoffman@finnpartners.com 

 

View original content:https://www.prnewswire.com/news-releases/alzpath-signs-global-licensing-agreement-with-abbott-to-advance-blood-based-alzheimers-disease-testing-302808974.html

SOURCE ALZpath, Inc.

FAQ

What did Abbott (NYSE: ABT) and ALZpath announce about Alzheimer’s blood testing on June 24, 2026?

Abbott and ALZpath announced a licensing agreement to develop an Alzheimer’s blood test using ALZpath’s pTau217 antibody. According to ALZpath, the test is intended for Abbott’s Alinity ci-series systems to support earlier and broader Alzheimer’s disease detection worldwide.

How will Abbott’s Alinity ci-series use ALZpath’s pTau217 antibody for Alzheimer’s diagnostics?

Abbott plans to incorporate ALZpath’s proprietary pTau217 antibody into an in vitro diagnostic test on its Alinity ci-series. According to ALZpath, these systems have one of the largest immunoassay install bases, potentially enabling wide access to blood-based Alzheimer’s testing globally.

Why is the ALZpath pTau217 antibody considered important for Alzheimer’s diagnosis?

ALZpath’s pTau217 antibody is described as highly validated for detecting Alzheimer’s disease pathology. According to ALZpath, it is backed by more than 200 peer-reviewed publications across 18 countries and shows high accuracy and sensitivity in identifying Alzheimer’s-related biology using blood-based biomarkers.

How could the Abbott and ALZpath licensing deal impact early Alzheimer’s detection for patients?

The agreement aims to expand access to blood-based tests that support earlier Alzheimer’s identification. According to ALZpath, a scalable blood assay on Abbott’s Alinity ci-series could bring high-performance diagnostics into routine and primary care, potentially reaching more clinicians and patients worldwide.

What advantages might blood-based Alzheimer’s biomarkers offer over PET or CSF testing?

Blood-based biomarkers may provide a more scalable alternative to PET imaging and cerebrospinal fluid analysis. According to ALZpath, PET and CSF methods can be costly, invasive and hard to deploy broadly, while blood tests could simplify earlier diagnosis and disease monitoring in routine practice.

How does the ALZpath collaboration support Abbott’s broader brain health strategy?

The collaboration is positioned as part of Abbott’s efforts to advance brain health diagnostics. According to Abbott, the company has spent over a decade in brain health science, including developing the first FDA-cleared rapid blood test helping assess mild traumatic brain injury using biomarker data.